Spring Mark E 4
4 · MEDIMMUNE INC /DE · Filed Jun 19, 2007
Insider Transaction Report
Form 4
Spring Mark E
VP, Finance & Controller
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2007-06-18−25,000→ 0 totalExercise: $24.23Exp: 2014-10-03→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2007-06-18−5,000→ 0 totalExercise: $24.17Exp: 2015-02-15→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2007-06-18−22,000→ 0 totalExercise: $36.78Exp: 2016-02-22→ Common Stock (22,000 underlying)
Footnotes (4)
- [F1]This option, which provided for vesting with respect to 1/4 of the shares on 10/04/2005 and with respect to the remaining shares in equal quarterly installments thereafter, was cancelled pursuant to the merger agreement between the issuer and AstraZeneca PLC in exchange for a cash payment of $33.77 per share, representing the difference between the exercise price of the option and $58.00 per share.
- [F2]This option, which provided for vesting in equal quarterly installments beginning 5/16/2005, was cancelled in the merger in exchange for a cash payment of $33.83 per share, representing the difference between the exercise price of the option and $58.00 per share.
- [F3]This option, which provided for vesting in equal quarterly installments beginning 5/23/2006, was cancelled in the merger in exchange for a cash payment of $21.22 per share, representing the difference between the exercise price of the option and $58.00 per share.
- [F4]This option, which provided for vesting in equal quarterly installments beginning 5/15/2007, was cancelled in the merger in exchange for a cash payment of $26.75 per share, representing the difference between the exercise price of the option and $58.00 per share.